Company: ARTL
Filing Date: 2025-12-11
Form Type: DEF 14A
Source: 0001640334-25-002308
Chunk: 30

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-12-11
Form: DEF 14A
Chunk 30
---
 and Director |     | 2023 |     |        | 485,417 |     |       | 251,203 |     |              |    251,644 |     |                       |     5,831 |     |       |   994,095 |

| (1) | In accordance with SEC rules, the amounts shown reflect the aggregate grant date fair value of stock awards granted to our named executive officer during the applicable year, computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718 (“FASB ASC 718”). The grant date fair value for stock options is measured based on the Black-Scholes Model. See Note 5 - Equity to our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 3, 2025. |
| (2) | New option awards granted in 2024 totaled $115,834 in grant date value. On February 28, 2024, previously issued options were repriced to $9.30 and had their vesting schedules modified as described below. As per ASC 718 the changes were treated as modifications to the options. This modification resulted in an aggregate increase in the incremental fair value of the repriced options, computed as of the February 28, 2024 modification date in accordance with ASC 718, in the amount $124,182..                                                                                  |
| (3) | This is comprised of health insurance premiums of $52,173 and life insurance premiums of $5,831.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

| 17 |

Outstanding Equity Awards at Fiscal Year-End December 31, 2024

The following table sets forth certain information regarding stock options granted to our named executive officer that remained outstanding as of December 31, 2024. Our named executive officer does not hold any restricted stock unit awards or equity awards other than stock options.

| Name                            |     | Number of Securities Underlying Unexercised Options: Exercisable 
 (1)                                                              |   |     | Number of Securities Underlying Unexercised Options:Unexercisable 
 (2)                                                               |              |     | Option Exercise Price 
 (3)                   |      |     | Option Expiration Date 
 (4)                    |
|:--------------------------------|:----|:-----------------------------------------------------------------|:--|:----|:------------------------------------------------------------------|:-------------|:----|:----------------------|